Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE-2: DOS + Toripalimab vs SOX + Toripalimab in Locally Advanced Gastric Adenocarcinoma
NCT03691454Phase 3Active, not recruiting
- Sponsor
- Peking University
- Start
- Jun 2018
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in gastric adenocarcinoma (2 arms), sponsored by Peking University. Primary endpoint: Pathologic Complete Response at 1 year. Started Jun 2018; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03691454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691454.